Letrozole versus clomiphene citrate in polycystic ovary syndrome: Systematic review and meta-analysis

Gynecological Endocrinology

Volumn 31, Issue 12, 2015, Pages 917-921

  Roque, Matheus ^a   Tostes, Ana C I ^a   Valle, Marcello ^a   Sampaio, Marcos ^b   Geber, Selmo ^b,c  

^a ORIGEN Center for Reproductive Medicine   (Brazil)

^b Origen Center for Reproductive Medicine   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Clomiphene citrate; letrozole; PCOS

Indexed keywords

CLOMIFENE CITRATE; LETROZOLE; AROMATASE INHIBITOR; CLOMIFENE; FERTILITY PROMOTING AGENT; NITRILE; TRIAZOLE DERIVATIVE;

ARTICLE; DATA BASE; EMBASE; HUMAN; LIVE BIRTH; MEDLINE; META ANALYSIS; MULTIPLE PREGNANCY; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; OVULATION; OVULATION INDUCTION; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; COMPARATIVE STUDY; COMPLICATION; FEMALE; INFERTILITY, FEMALE; PREGNANCY; PROCEDURES; PROSPECTIVE STUDY;

AROMATASE INHIBITORS; CLOMIPHENE; FEMALE; FERTILITY AGENTS, FEMALE; HUMANS; INFERTILITY, FEMALE; LIVE BIRTH; MEDLINE; NITRILES; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY RATE; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIAZOLES;

EID: 84951570570     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2015.1096337     Document Type: Article

References (39)

1. The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008; 89: 505-22
2. Meirow D, Laufer N, Schenker JG. Ovulation induction in polycystic ovary syndrome: A review of conservative and new treatment modalities. Eur J Obstet Gynecol Reprod Biol 1993; 50: 123-31
3. Legro RS, Brzysli RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med 2014; 371: 119-29
4. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-Term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25
5. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-Term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-7
6. Misso ML, Wong JLA, Teede HJ, et al. Aromatase inhibitors for PCOS: A systematic review and meta-Analysis. Hum Reprod Update 2012; 18: 301-12
7. Franks S, Adams J, Mason H, Polson D. Ovulatory disorders in women with polycystic ovary syndrome. Clin Obstet Gynecol 1985; 12: 605-32
8. Kurabayashi T, Suzuli M, Fujita K, et al. Prognostic factors for ovulatory response with clomiphene citrate in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2006; 126: 201-5
9. He D, Jiang F. Meta-Analysis of letrozole versus clomiphene citrate in polycystic ovary syndrome. Reprod Biomed Online 2011; 23: 91-6
10. Casper RF, Mitwally MF. A historical perspective of aromatase inhibitors for ovulation induction. Fertil Steril 2012; 98: 1352-5
11. Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 2001; 75: 305-9
12. Pavone ME, Bulun SE. Clinical review: The use of aromatase inhibitors for ovulation induction and superovulation. J Clin Endocrinol Metab 2013; 98: 1838-44
13. Requena A, Herrero J, Landeras J, et al. Reproductive Endocrinology Interest Group of Spanish Society of Fertility. Use of letrozole in assisted reproduction: A systematic review and meta-Analysis. Hum Reprod Update 2008; 14: 571-82
14. Pritts E. Letrozole for ovulation induction and controlled ovarian hyperstimulation. Curr Opin Obstet Gyn 2010; 22: 289-94
15. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-Analyses: The PRISMA statement. BMJ 2009; 339: 332-9
16. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. London: The Cochrane Collaboration; 2011
17. Higgins JP, Thompson SG, Deeks JJ, Altmann DG. Measuring inconsistency in meta-Analyses. BMJ 2003; 327: 557-60
18. Begum MR, Ferdous J, Begum A, Quadir E. Comparison of efficacy of aromatase inhibitor and clomiphene citrate in induction of ovulation in polycystic ovarian syndrome. Fertil Steril 2009; 92: 853-7
19. Zeinalzadeh M, Basirat Z, Esmailpour M. Efficacy of letrozole in ovulation induction compared to that of clomiphene citrate in patients with polycystic ovarian syndrome. J Reprod Med 2010; 55: 36-40
20. Kar S. Clomiphene citrate or letrozole as first-line ovulation induction drug in infertile PCOS women: A prospective randomized trial. J Hum Reprod Sci 2012; 5: 262-5
21. Bayar U, Kiran S, Coskun A, Gezer S. Use of an aromatase inhibitor in patients with polycystic ovary syndrome: A prospective randomized trial. Fertil Steril 2006; 5: 1447-51
22. Dehbashi S, Kazerooni T, Robati M, et al. Comparison of the effects of letrozole and clomiphene citrate on ovulation and pregnancy rate in patients with polycystic ovary syndrome. Iran J Med Sci 2009; 1: 19-26
23. Ray PB, Ray A, Chakraborti PS. Comparison of efficacy of letrozole and clomiphene citrate in ovulation induction in Indian women with polycystic ovarian syndrome. Arch Gynecol Obstet 2012; 285: 873-7
24. Roy KK, Baruah J, Singla S, et al. A prospective randomized trial comparing the efficacy of letrozole and clomiphene citrate in induction of ovulation in polycystic ovarian syndrome. J Hum Reprod Sci 2012; 5: 20-5
25. Atay V, Cam C, Muhcu M, et al. Comparison of letrozole and clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation. J Int Med Res 2006; 1: 73-6
26. Badawy A, Aal IA, Abulatta M, Caballero AE. Clomiphene citrate or letrozole for ovulation induction in women with polycystic ovarian syndrome: A prospective randomized trial. Fertil Steril 2009; 3: 849-52
27. Franik S, Kremer JA, Nelen WL, Farquhar C. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev 2014; 2: CD010287
28. Young SL, Opsahl MS, Fritz MA. Serum concentrations of enclomiphene and zuclomiphene across consecutive cycles of clomiphene citrate therapy in anovulatory infertile women. Fertil Steril 1999; 71: 639-44
29. Franasiak JM, Holoch KJ, Yuan L, et al. Prospective assessment of midsecretory endometrial leukemia inhibitor factor expression versus β3 testing in women with unexplained infertility. Fertil Steril 2014; 101: 1724-31
30. Miller PB, Parnell BA, Bushnell G, et al. Endometrial receptivity defects during IVF cycles with and without letrozole. Hum Reprod 2012; 27: 881-8
31. Wallace KL, Johnson V, Sopelak V, Hines R. Clomiphene citrate versus letrozole: Molecular analysis of the endometrium in women with polycystic ovary syndrome. Fertile Steril 2011; 96: 1051-6
32. Biljan M, Hemmings R, Brassard N. The outcome of 150 babies following the treatment with letrozole or letrozole and gonadotropins. Fertil Steril 2005; 84: O-231,. Abstract 1033
33. Tiboni GM. Aromatase inhibitors and teratogenesis. Fertil Steril 2004; 81: 1158
34. Tulandi T, Martin J, Al-Fadhii R, et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril 2006; 85: 1761-5
35. Casper RF, Mitwally MF. Use of the aromatase inhibitor letrozole for ovulation induction in women with polycystic ovarian syndrome. Clin Obstet Gynecol 2011; 54: 685-95
36. Sharma S, Ghosh S, Singh S, et al. Congenital malformations among babies born following letrozole or clomiphene for infertility treatment. PLoS One 2014; 9: E108219
37. Reefhuis J, Honein MA, Schieve LA, Rasmussen SA., National Birth Defects Prevention Study. Use of clomiphene citrate and birth defects, National birth defects prevention study, 1997-2005. Hum Reprod 2011; 26: 451-7
38. Davies MJ, Moore VM, Willson KL, et al. Reproductive technologies and the risk of birth defects. N Engl J Med 2012; 366: 1803-13
39. Palomba S. Aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab 2015; 100: 1742-7